

Emcure
cure and beyond



VISION & VALUES

“Harnessing science for better patient solutions.”



Emcure Values

EMCURE IN A SNAPSHOT

Global presence with significant international operations across key markets, including Canada, the UK, Europe, Africa, CIS, Asia, MENA, FWA, and other SRA countries.

Ranked **13th**
Pharmaceutical
company in India*

*as per IQVIA MAT June2026



Global Presence
70+ Countries
11,000+ Employees
500+ Scientists



13 Chirally Pure Molecules
2300+ Dossiers Filed
Globally
102 DMFs
219 Patents Granted



EMCURE JOURNEY- 1983-2026



INTERNATIONAL OVERVIEW

- **Strong track record** of inorganic expansion to **enhance markets** presence



Europe

tillomed



240 Approved Products

- We have established a strong presence across both retail and hospital segments in the UK, while maintaining a predominantly hospital-focused footprint in other **European markets**.



280 Products filed for regulatory approval ²

- Our growth is driven by a combination of robust front-end capabilities and strategic partnerships, ensuring a reliable and efficient supply chain.



122+ Products Launched

- We have **established subsidiaries** in Italy, Germany, the UK, Spain, and France.



Canada

MARCAN



135 Approved Products ¹

- **Differentiated product** portfolio marketed through our own front-end subsidiaries in Canada and channel partners across other markets.



190 Products filed for regulatory approval ¹

- **Presence across** retail, **Hospital and OTC segments**.



105+ Products Launched ¹

- **Acquired** a majority stake in **Mantra in 2023**.

Note: Data mentioned in Europe & Canada as of 2026. 1. For Europe - Out of the 280 products filed for regulatory approval, 240 have been approved. 2. For Canada - Out of the 190 products filed for regulatory approval, 135 have been approved.
* Data on File

INTERNATIONAL OVERVIEW

- **Developing products** in line with various **global regulatory** authorities.



Emerging Market*



1277

Approved Products ²

- Utilizes its strong front-end **capabilities and collaborates** with local and multinational partners to **drive business growth**.



1321

Products filed for regulatory approval ^{1,2}

- Leverages its extensive **India portfolio** and global product registrations to address **diverse market needs**.



650+


Products Launched ⁵

- Has established subsidiaries in **South Africa, Peru, the Philippines, Chile, Kenya, Dominican Republic, Mexico & Brazil**.



94

Emerging Market Countries Served ³



MENA / FWA



243

Approved Products

- **Emcure MENA** Regional Office** has established its subsidiary in Dubai to oversee and **manage business operations across the region**.



618

Products filed for regulatory approval [#]

- **Emcure French West Africa (FWA)** strengthens access to high-quality, affordable medicines and specialty therapies across the region, improving patient outcomes through trusted healthcare solutions.



60+

Products Launched


Note: 1. Out of the 1321 products filed for regulatory approval, 1277 have been approved. 2. Includes Dossiers filed, products launched and approved products (as applicable) for European Union and Canada. 3. Note: The above numbers exclude **European countries, Canada, and the USA**. However, **Turkey is included** in the count.

*Total 1,277 products have been dispatched to the country, out of which 745 products have been submitted to the MOH.

**Countries are Middle East, North Africa, FWA-French West Africa, Turkey, Afghanistan and Pakistan ^ Submissions at Boards of Health in various MENA markets with expected approvals within 1-2 Years

MENA Region - Number of products filed for regulatory approval : 262 and Number of products approved : 130 ## FWA Region Number of products filed for regulatory approval : 356 Number of products approved : 113

R&D Facilities



*We have five state-of-the-art R&D facilities in India.
Out of the five, we have three facilities focused on formulations research, one facility focused on API research and one facility focused on biopharmaceutical research.*

Biopharmaceuticals
and Vaccines, Pune



Formulations (Inj), Pune



API, Pune



Formulations, Pune



Formulations, Ahmedabad



EMCURE'S MANUFACTURING FACILITIES

API Kurkumbh, Pune



Approvals :

USFDA, EDQM (Europe), WHO Geneva, ANVISA Brazil, MFDS Korea.

Biotech Formulation, Pune



Approvals :

EU GMP, EAEU Russia, ANVISA Brazil, DIGEMID Peru, FDA Philippines, PPB Kenya, NMRA Srilanka, DAV Vietnam, NHRA Bahrain, NAFDAG Nigeria.

OSD, Pune



Approvals :

Health Canada, EU GMP, TGA Australia, EAEU Russia, GCC, ANVISA Brazil, WHO Geneva, ZAZIBONA.

OSD, Kadu, Ahmedabad



Approvals :

USFDA, EU GMP, Health Canada, ZAZIBONA, PPB Kenya, SAHPRA South Africa, NDA Uganda.

General Injectable & OSD, Mehsana, Ahmedabad



Approvals :

EU GMP, Health Canada, ANVISA Brazil, PPB Kenya, ZAZIBONA, TGA Australia, FDA Rwanda, Bahrain.

General & Oncology Injectables, Sanand, Ahmedabad



Approvals :

USFDA, EU GMP, Health Canada, EAEU Russia, ANVISA Brazil.

PORTFOLIO MATRIX CAPABILITIES IN GENERIC SPACE

1. Specialized Synthetics

A. Complex APIs (High Potency)

Challenging synthesis profiles, extreme barriers to entry, & niche manufacturing requirements.

- Eribulin
- Lurbinectidin
- Carmustine
- Melphalan

B. Chiral Switch (Isomer Isolation)

Advanced optical separations yielding pure enantiomer profiles with optimized pharmacokinetic margins.

- S-Amlodipine
- S-Metoprolol

C. Antiretrovirals (ARVs) (Virology)

Leading therapies tackling resistant strains and maintaining high-yield global patient backbones.

- Lenacapavir
- Islatravir
- Tenofovir D.
- Doravirine
- Dolutegravir

2. Delivery & Technology

A. Colloidal Iron Portfolio (Nano-Particles)

Precision colloidal chemistry with structural and thermodynamic stability in aqueous solutions.

- Iron Sucrose
- Ferric Carboxymaltose

B. Peptide Platforms (Liquid/Solid Phase)

Proprietary synthetic routes to yield ultra-pure polypeptide chains for niche treatments.

- Semaglutide
- Aviptadil
- Atosiban
- Difelikefalin

C. Photochemistry (Light Catalysis)

Novel photochemical reactions eliminating harsh catalysts and ensuring pure green-chemistry yields

- Dydrogesterone

ADVANCED DRUG CAPABILITIES FORMULATION AND DELIVERY PLATFORM

1. Advanced Parenterals

A. Complex Injections (Liposomal Technology)

Specialized lipid-based nanoparticle delivery systems. Designed to improve targeted tissue delivery.

Key Molecules:

- Lipo Amphotericin B
- Lipo Doxorubicin
- Lipo Bupivacaine

B. Long Acting Injections (Depot System)

Extended – release microsphere and biodegradable polymer technology

Key Molecules:

- Lanreotide
- Semaglutide

2. Mucosal & Respiratory

A. Nasal and Inhalation (Device Integrated)

Direct to membrane non-invasive delivery.

Utilizing precision devices and dry/Liquide inhalation technology

Key Molecules:

- Rizatriptan Nasal Spray
- Lipo Amikacin (Inhalation)

B. Sublingual Tablets (Rapid Absorption)

Fast-disintegrating oral mucosal system bypassing first pass hepatic metabolism for rapid onset of kinetics

Key Molecules:

- Progesterone
- Dydrogesterone

3. Targeted & Osmotic

A. Osmotic Delivery (Zero Order Release)

Semi-permeable membrane based laser drilled delivery system enabling constant, zero order drug release profile

Key Molecules:

- Prazosin

B. Topical Dosage Forms (Local / Dermal)

Formulations with optimized lipid /aqueous partitions designed for precise epidermal penetration and local efficacy

Key Molecules:

- Cidafovir
- Tapinarof



Liposomal Amphotericin B Injection

- ◆ Approved by USFDA, UKMHRA, EU & ISP-Chile.
- ◆ Engineered with advanced liposomal technology with robust R&D and world-class manufacturing capacity.
- ◆ Exceptional stability and superior shelf life (5 year).
- ◆ Proven safety profile with minimal free drug which is expected from any Liposomal drug delivery.
- ◆ Consistent quality supply across globe with batch-to-batch consistency & stringent quality & characterization parameters.

FROM THE HOUSE OF CHIRALS

Asomex[®]-2.5/5

S(-) Amlodipine Tablets 2.5 / 5 mg

METPURE-XL
S(-)Metoprolol ER Tabs 50 mg

Proxym[®]-300

S(+) Etodolac Extended Release Tablets 300 mg

Infen[™]-25


Dexketoprofen Tablets 25 mg

PanPure[®]

S(-) Pantoprazole Sodium 20 mg Tablets

DexPure[™]

Dexketoprofen Sodium Tablets 10 mg



BIOSIMILARS IN FOCUS

TENECTASE[®]

Tenecteplase for Injection 20 mg

Elaxim
Tenecteplase for injection 40 mg / 52.5 mg

Vintor[®]

Pre-filled Syringe - 2000/4000 IU

HAMSYL[®]

Pegaspargase Injection 3750 IU / 5ml

Encicarb

Ferric Carboxymaltose Injection

Iron Sucrose Injection USP
Encifer[®]

Orofer[™]

Iron (III) - Hydroxide Polymaltose Complex & Folic Acid
Iron (III) - Hydroxide Polymaltose Complex
Capsules
Syrup

Zemcifer[®] Tab.
Susp.

Ferrous Ascorbate equivalent to elemental iron 50 mg Tablet
Ferrous Ascorbate equivalent to elemental iron 30 mg Suspension

In progress — • Ophthalmic Bevacizumab (for WAMD)
• Recombinant L- Asparaginase
• Recombinant Peg Asparaginase

CRITICAL CARE AND NEOPLASTIC PRODUCT RANGE

Pause^{Inj}

Tranexamic Acid Injection BP

Lomoh
Enoxaparin Sodium 40/60/80 mg Injection
(Low Molecular Weight Heparin)

Sylate[®]

Etamsylate 500 mg Tab

Treosulfan

Treosulfan 5g powder for solution for infusion

MELPHALAN

Melphalan Hydrochloride Injection 50 mg

BiCNU

Carmustine Inj. 100 mg

EMCURE'S ANTIRETROVIRALS RANGE

Coming Soon

Lenacapavir Injections
Lenacapavir Tablets

Siropil[™]

50/300/300 mg

INBEC

Dolutegravir 50 mg/Abacavir 600 mg/
Lamivudine 300 mg Tablets

INSTGRA

Dolutegravir 50mg Tab

Spegra[™]

Dolutegravir 50 mg/Emtricitabine 200 mg/
Tenofvir Alafenamide 25 mg Tablets

TAVIN[®]-EM


Tenofvir Disoproxil Fumarate 300 mg/
Emtricitabine 200 mg tablets

TWINAQT

Dolutegravir 50mg / Lamivudine 300mg Tablets

Nuace

Darunavir 800 mg/Ritonavir 100 mg



API KEY HIGHLIGHTS

EMCURE API



Robust Research & Development
Expertise Driving Multiple
First-to-Market Innovations



Fast-Growing and Diversified
International Business



Established Track Record of Meeting
Global Regulatory Standards



Pioneers in Chiral and Complex APIs,
Driven by Differentiated Technologies

STRONG R&D CAPABILITIES

Complex Molecules



Continuous Product & Process Improvements

- Chiral molecules technology -13 Molecules
- Ferric CarboxyMaltose - 1st to launch in India
- Dydrogesterone - Photo chemistry technology
- Eribulin - 1st global generic launched in India
- Treprostinil in PAH*

- New manufacturing processes for ARV* APIs - lower production costs
- Advancing flow chemistry technology
- Industrial level photochemical reaction capability
- Striving to achieve greener technology

*ARV - Anti-retroviral

*PAH - Pulmonary Arterial Hypertension

PREFERRED PARTNER FOR GLOBAL INNOVATORS

WHY PARTNER WITH EMCURE?



Track Record

Illustrious track record
of successful
partnerships resulting
in wealth creation for all



IP Protection

Emcure has consistently
protected interest of the
innovators through
safeguarding the
innovation



Execution Capabilities

- Strong technological platform capable of handling complex products
- Wide reach to ensure commercial success

PARTNERS WE PROUDLY COLLABORATE WITH

abbvie


Ritonavir

 GILEAD

TAF / Emtricitabine /
Bictegravir / Lenacapavir


Bristol-Myers Squibb

Atazanavir

 medicines
patent
pool

 MSD

Molnupiravir / Doravirine
Islatravir/ Alimatravir

sanofi

Ramipril / Enoxaparin Sodium /
Furosemide

tibotec
DIVISION OF JANSSEN-CILAG GmbH

Darunavir

 Vifor

IP license to manufacture /
Commercialize Ferric
CarboxyMaltose in India


ViiV
Healthcare

Dolutegravir / Abacavir /
Maraviroc Lamivudine

 Roche

Mycophenolate mofetil /
Methoxy polyethylene
glycol-epoetin beta


novo nordisk®

r-DNA origin
Semaglutide Injection

DIVERSIFIED INTERNATIONAL BUSINESS



HEADQUARTERS

OPERATING SUBSIDIARY

BRANCH OFFICE

REPRESENTATIVE OFFICE

Emcure Pharmaceuticals Ltd. Pune

Registered Office Address: Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune-411057, Maharashtra, India
Tel.: +91 20 39821000 | **Fax:** +91 20 39821019

Address: A-301, Ganga Osian Square, Wakad, Pune - 411057, India
Tel.: +91 20 66770000 / 27717000

Website: www.emcure.com

Emcure Pharmaceuticals Ltd. Mumbai

Address: D-Wing, Unit No. 5119-5148, 5th Floor, Oberoi Garden Estates, Near Chandivali Studio, Chandivali, Andheri (E), Mumbai - 400 072 **Tel.:** +91 22 69420000

Branch / Representative Offices

Emcure Pharmaceuticals Limited , Myanmar

Address: Room No - 407, Building (B), Space @ Yankin Condo, Yan Shin Road, 5th Block, Yankin Township, Yangon, Myanmar
Email Address: Swapnil.Sonawane@emcure.com

VPDD Emcure Pharmaceuticals Limited, Vietnam

Address: G 516, Manor 2 Officetel, 91 Nguyen, Huu Canh, Ward 22, Binh thanh Dist., HCMC, Vietnam
Email Address: Vinish.Jain@emcure.com

Russia/CIS

Address: Ochakovskoye, shosse, 34, Office B801, Moscow, Russia, 119530
Email Address: Vanraj.Tilekar@emcure.com | Salim.Shaikh@emcure.com

INTERNATIONAL PRESENCE- OPERATING SUBSIDIARY

Emcure Pharmaceuticals Mena FZ-LLC

Address: Al-Baker Building 26, Floor 6, Office 608 & 609,
Dubai Health Care City, Dubai, UAE

Email Address: Amr.Elneklawy@emcure.com

Tel.: +0971 5291 78541

Emcure Pharma Peru S.A.C, Peru

Address: Av. Circunvalacion del Golf los Incas 170
Torre More of. 1803 - Surco

Email Address: Nikhil.Deshmukh@emcure.com

Emcure Pharma Chile SPA, Chile

Address: AV. Apoquindo N° 6410, Office 1001,
Comuna: Las Condes, City: Santiago

Email Address: Fernando.Portugal@emcure.com

Emcure Pharmaceuticals South Africa (Pty) Limited

Address: Arizona House, First Floor, South Wing, 1 Madison Avenue
Aspen Lakes, Ext 13, Gauteng 2190, Johannesburg, South Africa

Email Address: BalajiUD@emcure.com

Emcure Pharmaceuticals Pty Ltd, Australia

Address: Suite 807, 109 Pitt Street, Sydney, NSW
2000, Australia

Email Address: Srinivas.Maddali@emcure.com

Emcure Pharma Philippines Inc.

Address: Unit 1201, Frabelle Business Center, 111 Rada Street,
Legaspi Village, Makati City, Metro Manila-1229 ,Philippines

Email Address: Srinivas.Maddali@emcure.com

Tel.: +632 53102390

Emcure Pharmaceuticals Dominicana, SAS

Address: 4th Floor, Plaza Comercial ESUAR, Lorenzo Despradel
Street No. 51, Santo Domingo De Guzman, Dominican Republic

Email Address: Shivaprasad.C@emcure.com

Tel.: +254 719 561485

Emcure Pharma Mexico S.A. DE C.V.

Address: Boulevard Adolfo Ruiz Cortines 3720, Torre 2, Piso 9,
Oficina 09a125 Jardines Del Pedregal Ciudad De Mexico

Alvaro Obregon C.P.01900

Emcure Brazil Pharmaceuticals Ltda

Address: Avenida Benedito Isaac Pires, No. 600, Sala 01,
Parque Dom Henrique, Cidade de Cotia, Estado de São Paulo,
CEP 06716-300, Brazil

Email Address: Shivaprasad.C@emcure.com

Lazor Pharmaceuticals Limited, Kenya

Address: Westside Tower, Off Roun Dabout of Lower Kabete Road,
Brookside Drive,Westlands, P.o Box 33831, Nairobi- Kenya

Email Address: digvijay.rajput@emcure.com

Tel.: +91 81711817187 / +254741655567

Emcure Nigeria Limited

Address: 29, Adeniyi Jones Avenue, Oba Akran, Ikeja, Lagos, Nigeria.

UK, EUROPE & CANADA ENTITIES

Tillomed Laboratories Ltd

Address: 220 Butterfield Great Marlings, Luton, LU2 8DL UK

Email Address: customer.service@tillomed.com

Tel.: +44 (0)1480 402400

Laboratorios Tillomed Spain SLU

Address: : Calle Marcelo Spinola 8, planta 1,
Puerta F, 28016, Madrid, Spain

Tillomed France SAS

Address: : 35 Rue des Chantiers 78000 Versailles,
France

Tillomed Malta Ltd.

Address: : Tower Business Centre, 2nd Floor, Tower Street,
Swatar, Birkirkara, BKR4013, Malta

Marcan Pharmaceuticals Inc.

Address: 2 Gurdwara Road, Suite #112 Ottawa, ON, K2E 1A2, Canada

Email Address: info@marcanpharma.com

Tel.: CAN +1 (613)-228-2600

Emcure Pharma UK Ltd

Address: 220 Butterfield, Great Marlings,
Luton, England, LU2 8DL, UK

Tillomed Pharma GmbH

Address: Mittelstraße 5/5a, 12529,
Schönefeld, Germany

Tillomed Italia SRL

Address: Viale Giulio Richard, 1 – Torre A, 20143
Milan (Italy)

Mantra Pharma Inc.

Address: 1000 Du Lux Street, Suite 201 Brossard,
Quebec J4Y 0E3 Canada

Email Address: medinfo@mantrapharma.ca

Tel.: 450-678-7088

GLOBAL ACCREDITATIONS



U.S. Food and Drug Administration



European Directorate for the Quality of Medicines & HealthCare, Europe



Therapeutic Goods Administration (TGA), Australia



Health Canada



Medicines and Healthcare products Regulatory Agency, UK



World Health Organization (WHO), Geneva



MFDS (Ministry of Food and Drug Safety), Korea



Brazilian Health Regulatory Agency (ANVISA) Brazil



Central Drugs Standard Control Organization (CDSCO), India



Ministry of Health & Family Welfare, India



COFEPRIS - Mexico Ministry of Health



Gulf Cooperation Council (GCC)



Ministry of Health, Ukraine



Ministry of Health, Libya



Ministry of Health, Kuwait



Ministry of industry and Trade of the Russian Federation



NMRA, Sri Lanka



Food and Drugs Authority, Ghana



Food and Drug Authority, Rwanda



Ethiopia Food and Drug Authority (Ethiopia FDA)



Medicines Control Authority of Zimbabwe



National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria



National Drug Authority, Uganda



Pharmacy and Poisons Board, Kenya



Pharmacy & Medicines Regulatory Authority, Malawi



South African Health Products Regulatory Authority (SAHPRA)



Tanzania Medicines & Medical Devices Authority (TMDA)



TFDA, Thailand



FDA, Philippines



National Institute of Pharmacy & Nutrition (OGYEI) Hungary, (EU-GMP)

Emcure
cure
and beyond



PRODUCT LIST 2026

EMERGING MARKETS

ANTI-HISTAMINE

Sr. No.	Molecule	Form	Strength	Status
1	Bilastine	Tablet	20mg	Available
2	Cetirizine	Oral Solution	5 mg/5 ml 60 ml	Under Development
3	Desloratidine	Oral Solution	0.5mg/ml	Available
4	Levocetirizine	Tablet	5mg	Available
5	Levocetirizine	Oral Solution	2.5 mg/5ml, 30 ml & 60 ml	Under Development

ANESTHESIOLOGY

1	Dexmedetomidine	Injection	200mcg/2mL	Available
---	-----------------	-----------	------------	-----------

CARDIOLOGY

1	Apixaban	Tablet	2.5/5mg	Available
2	Clopidogrel	Tablet	75mg	Available*
3	Enoxaparin	PFS	20mg/0.2ml, 40mg/0.4ml, 60mg/0.6ml, 80mg/0.8ml	Available
4	Flecainide	Tablet	50/100mg	Available
5	Levocarnitine	Oral Liquid	500mg/5ml, 100 ml	Under Development
6	Levosimendan	Injection	2.5 mg/ml (12.5mg/5ml)	Under Development
7	Losartan & Hydrochlorothiazide	Tablet	50mg + 12.5mg	Under Development
8	Midodrine HCL	Tablet	2.5/5/10mg	Available
9	Milrinone	Injection	10mg/10mL	Available
10	Perindopril	Tablet	2/4/8mg	Available
11	Rivaroxaban	Tablet	10/15/20 mg	Available
12	Rosuvastatin	Tablet	5/10/20/40mg	Available
13	S (-) Amlodipine Besilate	Tablet	1.25/2.5/5mg	Available
14	S(-) Amlodipine Besilate + Losartan potassium	Tablet	2.5/50 & 5/50 mg , 2.5/100 & 5/100mg	Under Development
15	S (-) Amlodipine Besilate & Hydrochlorothiazide	Tablet	2.5mg/12.5mg	Under Development
16	S(-) Metoprolol	Tablet (ER)	12.5/25/50mg	Under Development
17	Sacubitril + Valsartan	Tablet	50/100/200 mg	Under Development
18	Telmisartan	Tablet	20/40/80 mg	Available
19	Telmisartan + Hydrochlorothiazide	Tablet	40/ 80 mg	Available
20	Tenecteplase	Injection	40/50 mg/Vial	Available
21	Losartan	Tablet	50mg + 12.5mg	Available
22	Atrovastatin	Tablet	10/20mg	Available

DIABETOLOGY / ENDOCRINOLOGY

1	Acarbose	Tablet	50/100mg	Available
2	Cinacalcet	Tablet	30/60 mg	Available
3	Empagliflozin	Tablet	10/25 mg	Under Development
4	Linagliptin	Tablet	5 mg	Under Development
5	Metformin ER	Tablet	500/750/1000mg	Available
6	Vildagliptin	Tablet	50mg	Available
7	Vildagliptin + Metformin	Tablet	50mg + 500/850/1000mg	Available

GASTROENTEROLOGY

1	Dexrabeprazole	Tablet	10mg	Available
2	Domperidone	Suspension	10mg/ml	Under Development
3	Esomeprazole	Injection	40mg/ vial	Available
4	Omeprazole	Capsule	20mg	Available*
5	S (-) Pantoprazole	Tablet	20mg	Available
6	Sucralfate	Suspension	1gm / 5ml, 200 ml	Under Development

PRODUCT LIST 2026

EMERGING MARKETS

GYNECOLOGY

Sr. No.	Molecule	Form	Strength	Status
1	Cetrorelix	Injection	0.25mg/ml	Under Development
2	Dydrogesterone	Tablet	10mg	Under Development
3	Dydrogesterone + Estradiol	Tablet	2.5mg + 0.5mg, 5mg + 1mg	Under Development

HEMATOLOGY

1	Deferasirox	Dispersible Tablet	125/250/500 mg	Under Development
2	Erythropoetin	PFS	2000/4000/6000/10000 I.U	Available
3	Etamsylate	Tablet	500mg	Available
4	Ferric Carboxy Maltose	Injection	50mg/ml,2ml,10ml,15ml and 20ml	Available
5	Ferrous Ascorbate	Tablet/Syrup	50mg, 30mg/5ml	Available
6	Iron Polymaltose	Syrup	50mg/150ml	Available
7	Iron Sucrose	Injection	100mg/5ml	Pipeline
8	Tranexamic acid	Injection	500mg/5ml	Available
9	Tranexamic acid	Tablet	500mg	Available
10	Tranexamic Acid and Mefenamic Acid	Tablet	500mg + 250mg	Available*

IMMUNOLOGY / RHEUMATOLOGY

1	Deflazacort	Oral suspension	22.75 mg/ml 30 ml	Under Development
2	Leflunomide	Tablet	10/20mg	Available
3	Mycophenolate	Tablet	360mg	Available
4	Mycophenolate Mofetil	Capsules / Tablet	250mg	Available
5	Mycophenolate Mofetil	Tablet	500mg	Available
6	Zoledronic Acid	Injection	4mg/5ml	Pipeline

NEUROLOGY / NEUROPSYCHIATRY

1	Atomoxetine	Oral Solution	4mg/ml	Available
2	Buspirone	Tablet	5mg & 10mg	Under Development
3	Duloxetine	Capsule	30/60mg	Available
4	Eszopiclone	Tablet	1/2/3mg	Available
5	Fingolimod	Capsule	0.5mg	Available
6	Leflunomide	Tablet	10/20mg	Available
7	Leviteracetam	Oral Liquid	100mg/mL	Under Development
8	Lurasidone	Tablet	20/40/80mg	Under Development
9	Modafinil	Tablet	100/200mg	Under Development
10	Naratriptin	Tablet	2.5mg	Under Development
11	Rasagiline	Tablet	0.5/1mg	Under Development
12	Rizatriptan	OD Tablet	5/10mg	Available
13	Valproic Acid	Oral Syrup	250mg/5ml 120 ml	Under Development

INFECTIOUS DISEASES

1	Amikacin	Injection	250mg/ml	Available
2	Cefuroxime Axetil	Tablet	250/500mg	Available
3	Ciprofloxacin	Tablet	500mg	Available*
4	Itraconazole	Capsule	100/200mg	Available
5	Liposomal Amphotericin B	Injection	50mg/Vial	Available
6	Metronidazole	Oral suspension	200 mg/ml 60 ml	Under Development
7	Nitrofurantoin	Capsule	50/100mg	Available

PRODUCT LIST 2026

EMERGING MARKETS

METABOLISM DISORDERS

Sr. No.	Molecule	Form	Strength	Status
1	Febuxostat	Tablet	40/80mg	Available
2	Trientine	Capsule	250mg	Available

NEPHROLOGY

1	Paricalcitol	Injection	5mcg/ml	Under Development
2	Sevelamer Carbonat	Tablet	800mg	Available
3	Tacrolimus	Tablet	0.5mg/ml	Available

ONCOLOGY

1	Arsenic Trioxide	Injection	10mg/10mL	Available
2	Azacitidine	Injection	100mg/vial	Pipeline
3	Bortezomib	RTU Injection	2.5 mg/mL (1.1 & 1.63 ml)	Pipeline
4	Busulfan	Injection	60mg/10ml	Available
5	Carmustine	Injection	100mg	Available
6	Eribulin	Injection	0.5mg/ml	Available
7	Filgrastim	Injection	300mcg/0.5ml	Available
8	Liposomal Doxorubicin	Injection	2mg/ml (20ml & 50ml)	Under Development
9	Melphalan	Injection	150mg/vial	Available
10	Pegaspargase	Injection	3750IU/5ml	Available
11	PegFilgrastim	Injection	300mcg/0.5ml	Available
12	Treosulfan	Injection	5g powder for infusion	Available

PAIN MANAGEMENT - NSAID / OPIOID

1	Diclofenac	Gel	1%	Available
2	Dexketoprofen Trometamol	Gel	12.5mg	Available
3	Dexketoprofen Trometamol	Injection	50mg/2ml	Under Development
4	Dexketoprofen Trometamol	Tablet	125mg	Available
5	Baclofen	Tablet	10/25mg	Available*
6	Paracetamol	Oral suspension	120mg/5ml	Under Development

BIOSIMILARS IN FOCUS

TENECTASE®

Tenecteplase for Injection 20 mg



Elaxim

Tenecteplase for injection 40 mg / 52.5 mg



HAMSYL®

Pegaspargase Injection 3750 IU / 5ml



PRODUCT LIST 2026 EMERGING MARKETS

Emcure
cure and beyond

FROM THE HOUSE OF CHIRALS

Asomex-2.5/5

S(-) Amlodipine Tablets 2.5 / 5 mg



METPURE-XL
S(-)Metoprolol ER Tabs 50 mg



Proxym-300

S(+) Etodolac Extended Release Tablets 300 mg



Infen-25

Dexketoprofen Tablets 25 mg



PanPure

S(-) Pantoprazole Sodium 20 mg Tablets



DexPure

Dexabeprozole Sodium Tablets 10 mg



IRON FORMULATIONS FOR ANEMIA MANAGEMENT

Encicarb

Ferric Carboxymaltose Injection



Iron Sucrose Injection USP
Encifer



Orofer

Iron (II) - Hydroxide Polymaltose Complex & Folic Acid Capsules Syrup



CRITICAL CARE AND NEOPLASTIC PRODUCT RANGE

Pause

Tranexamic Acid Injection BP




Lomoh

Enoxaparin Sodium 40/60/80 mg Injection (Low Molecular Weight Heparin)



Sylate

Etamsylate 125 mg Inj





Emcure
cure
and beyond

For more information please visit [Emcure website](http://www.emcure.com)

Emcure Pharmaceuticals Ltd.

Plot No. P-1 and P-2, IT-BT Park, Phase II, M.I.D.C., Hinjawadi, Pune-411057, Maharashtra, India
Tel.: (020) 39821000 | Fax: (020) 39821019 | www.emcure.com

A-301, Ganga Osian Square, Survey No. 249/250, Wakad, Pune-411057, India | Tel.: +91 20 66770000 / 27717000